| Y | | | | | | | | | | |
| HT | | | | | | | | | | |
| | HT | HT | HT | HT | HT | HT | HT | HT | HT | HT |
| | CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD |
| Y | | | | | | | | | | |
*For E+P, when intervention stopped July 9, 2002. For E-Alone, when intervention stopped in February 2004. | | | | | | | | | | | HT |
*At CaD study close-out October 2004-March 2005. | | | | | | | | | | | CaD |
| Y | | | | | | | | | | |
| Y | | | | | | | | | | |
| Y | | | | | | | | | | |
Collected every 6 months for HT ppts | | Y | Y | Y | Y | Y | Y | Y | Y | Y | CT |
If an event that needed adjudication was found on the form 33, a 33D was collected. |
| Y | | | | | | | | | | |
| | CT | | CT | | | CT | | | CT | |
| Y | | | | | | | | | | CT |
| | CT | | CT%/OS | | | CT% | | | CT% | |
*HT cohort aged 65 and over. | HT% | HT% | | HT% | | | HT% | | | HT% | |
| Y | | | | | | | | | | |
*Initiated in 2002 and collected once from all CT and OS participants at next routine contact. |
| OS | | | | | | | | | | |
| Y | | | | | | | | | | |
| Y | CT | | Y | | | CT | | | CT | |
| Y | CT | | Y | | | CT | | | CT | |
| | OS | | | | | | | | | |
*For E+P participants on study through July 8, 2002, when intervention was stopped; administration began in March 2003. |
entered if ppt needed to modify their study medication dosage |
*For all E-Alone participants; administered twice: |
*Year 2: 30% cross sectional 33% rotating subsample starting in the year 2000, such that for year 3 and each subsequent year each DM participant received an FFQ at once every 3 years. | Y | DM | DM% | DM%/OS | DM% | DM% | DM% | DM% | DM% | DM% | |
| Y | CT | CT | Y | CT | CT | CT | CT | CT | CT | |
| Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | |
Administered as indicated and as needed to manage unexpected bleeding. Not required after July 9, 2002, when intervention was stopped. *5% E+P participants with uterus | HT | | | HT% | | | HT% | | | HT% | |
*Done only if endometrial aspiration could not be done or was refused. |
*Optional for DM participants. | Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | |
| Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | HT |
| CT | | | CT | | | CT | | | CT | |
*Collected for ppts enrolled at 3 clinical centers or about 6-7% of total WHI. Yr1 collection limited to CT | % | % | | % | | | % | | | % | |
*Sample was selected from the HT and DM > 65 years old. | CT% | | | CT% | | | CT% | | | CT% | |
| Y | | | | | | | | | | |
*6% CT subsample. Year 6 collection was plasma only | Y | Y | | CT%/OS | | | CT%/OS | | | CT% | |
*% - Collected at 3 BMD clinical centers. Year 9 collection was for 25% of OS ppts | CT/OS% | CT% | | CT/OS% | | | CT% | | | OS% | |
| | | | OS | | | | | | | |
| | | | | OS | | | | | | |
| | | | | | OS | | | | | |
| | | | | | | OS | | | | |
| | | | | | | | OS | | | |
| | | | | | | | | OS | | |
*For OS participants who did not reach Year 7 by Closeout | | | | | | | | | | | OS |
Questionnaire | Baseline | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Closeout |
---|